HSG

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Normunity is a biotechnology company focused on developing precision immuno-oncology medicines, specifically a new class known as immune normalizers. These medicines aim to target novel mechanisms that enhance the body’s natural immune response against cancer. In collaboration with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is researching newly-discovered mechanisms of immune disruption in cancer, utilizing proprietary discovery platforms to explore the intricate interactions between cancer and the immune system. The company is advancing a pipeline of immune normalizers, which includes initial drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune function in cancer. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Cloudphysician is a prominent provider of Smart-ICU services, utilizing a cloud-based platform to enhance critical care delivery. The company employs advanced technologies such as artificial intelligence, the Internet of Things, and predictive analytics to facilitate real-time clinical decision-making. This innovative approach supports early-stage diagnosis of critical diseases in adults and monitors immunization schedules and growth profiles of newborns, aimed at reducing neonatal mortality rates. By combining medical expertise with technology, Cloudphysician improves patient outcomes and offers hospitals and healthcare providers enhanced monitoring, support, and training, ultimately transforming the landscape of critical care in the healthcare industry.

Black Jade Star Rock develops organoid-based intelligent equipment and chips. It is a biomedical research and development company with organoid science as its fundamental technology.

Generation Lab is focused on enhancing human health through the development of biological age testing services. The company aims to create a test that accurately assesses an individual's biological age and associated disease risks, utilizing clinically applicable biological evidence. By providing clinical-grade longevity reports and health span data analysis, Generation Lab enables healthcare professionals to optimize specific health areas based on the latest genomic research. The goal is to empower individuals to live longer and healthier lives by gaining insights into their biological age progression.

Full-Life Technologies is a radiotherapeutics company focused on the research, development, production, and commercialization of radiopharmaceuticals aimed at cancer therapy. The company specializes in targeted cancer treatment, leveraging advancements in nuclear medicine to enhance clinical outcomes for patients. By prioritizing innovative radiopharmaceutical research, Full-Life Technologies aims to improve treatment results for those affected by cancer, demonstrating a commitment to delivering significant clinical impact in the field of oncology.

Twin Health, Inc. is a precision health company focused on reversing diabetes and chronic diseases through its innovative health platform. Founded in 2018 and based in Mountain View, California, with additional offices in India, Twin Health utilizes artificial intelligence and Internet-of-Things technologies to accurately measure and address metabolic health issues, which are often the underlying causes of chronic conditions. The platform incorporates sensors and advanced machine learning to analyze biosignals from wearables, predict metabolic outcomes, and provide personalized treatment recommendations tailored to each patient's metabolic profile. The company has secured significant funding from prominent venture capital firms and holds multiple patents related to its technology, positioning it as a leader in the field of metabolic health.

FUE Bioscience is a medical robot R&D business that specializes in microsurgery above the head and neck. It continues to develop a product matrix of fully intelligent, high-precision, and anthropomorphic surgical robots based on the platform of macro-micro-controlled humanoid dual-arm robots.

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

HealiRNA develops infectious disease vaccines, tumor vaccines, cell therapy, and protein replacement. They provide mRNA drug research and development, production, clinical trial design, and data analysis services.

NeuroXess is a high-tech life science company focusing on flexible electrode BCI (Brain-computer interface) technologies to protect and explore the brain.

GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment. Founded in 2020, GenAssist was founded by outstanding scientists and industry experts in July 2020. They are committed to the development of gene editing drugs for a variety of genetic diseases.

Yangqi Intelligent provides answers for medical equipment. It provides goods like qise, elixir, wonder vision, odd control, and more. A self-made radiation body surface monitoring camera is called wonder vision. Qice is a platform for artificial intelligence-based medical models. Sales.

RedBrick AI is a software-as-a-service platform focused on annotating medical data, particularly in the field of radiology. It offers specialized web-based annotation tools for both 2D and 3D medical imagery, which can be seamlessly integrated into existing data storage systems used by healthcare providers. The platform is designed to streamline the annotation process by allowing clinicians to access robust tools directly through their browsers. Additionally, it features functionalities such as workflow control, user management, task assignment, and custom validation checks. These capabilities enable hospitals and medical associations to efficiently manage annotations and facilitate their integration with machine learning operations, ultimately supporting the development of healthcare artificial intelligence.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

WuXi Bo Rui Biotechnology develops a radioactive molecular imaging and nuclear drug transformation platform for the precise diagnosis and treatment of tumors. WuXi Bo Rui Biotechnology focuses on the transformation and development of new radionuclide drugs, covering multiple fields of small molecules, peptides, and antibodies, for the diagnosis and treatment of tumors, using their professional platform for targeted precursor design, screening, and radionuclide labeling. While increasing the efficiency of research and development, it also fully utilizes the benefits of accurate nuclear medicine diagnosis and treatment

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

Full-Life Technologies is a radiotherapeutics company focused on the research, development, production, and commercialization of radiopharmaceuticals aimed at cancer therapy. The company specializes in targeted cancer treatment, leveraging advancements in nuclear medicine to enhance clinical outcomes for patients. By prioritizing innovative radiopharmaceutical research, Full-Life Technologies aims to improve treatment results for those affected by cancer, demonstrating a commitment to delivering significant clinical impact in the field of oncology.

Hao Microbiology is a developer of vascular interventional embolization products.

CureFun is an online education portal specializing in medical education services. The company provides a comprehensive platform for medical students that includes training process management, theoretical learning, self-assessment, and examination services. Additionally, CureFun offers intelligent question bank recommendations to enhance the learning experience. Their innovative platform features realistic simulations of clinical scenarios, allowing students to practice and develop critical clinical thinking skills through interactive virtual exercises. This blend of theoretical knowledge and practical application positions CureFun as a valuable resource for aspiring medical professionals.

XISOFT is a professional manufacturer specializing in informatization and data services within health economic management. The company develops an enterprise resource planning (ERP) platform tailored for hospitals, providing comprehensive management and monitoring capabilities across various functions, including finance, supply chain, human resources, and diagnosis-related groups. By leveraging technology, XISOFT aims to support medical institutions in streamlining operations and enhancing efficiency. Its platform enables effective business integration and refined management, addressing key areas such as intelligent finance, material assets, internal control, and event management. Through its innovative solutions, XISOFT assists healthcare providers in realizing their strategic objectives and improving overall operational effectiveness.

Grit Science is a biotechnology company specializing in gene therapeutics, particularly focusing on the research and development of liver-related genes. The firm is dedicated to creating medical products and genetic treatments that address clinical needs and enhance human health. Through its innovative approach to biopharmaceutical technology, Grit Science aims to contribute significantly to the field of medicine by developing solutions that improve patient outcomes.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish a platform using platelet cells as a drug delivery carrier.

SceneRay Co. Ltd, based in Singapore Industrial Park, Suzhou, China, specializes in the design, development, and distribution of neuromodulation devices, particularly focusing on brain pacemakers. The company’s core team comprises experts with extensive experience in neuromodulation device development, manufacturing, and marketing, both in China and internationally. SceneRay's product offerings include a dual-channel implantable pulse generator kit designed for deep brain stimulation, which provides therapeutic electric stimulation to address issues related to brain damage. Committed to innovation, SceneRay holds numerous patents and strives to deliver high-quality, effective treatments for patients.

Sirka is Indonesia's pioneering metabolic clinic, focused on healthcare innovation through a technology-enabled, holistic approach to managing obesity and metabolic health. The clinic addresses the root causes of weight gain and chronic diseases, offering services that include weight management, digestive health, diabetes care, and chronic disease management. Sirka provides personalized, clinically proven programs tailored to individual needs, combining expert medical care with customized nutrition plans and continuous monitoring. Clients can connect with dietitians through an application, allowing them to set health goals and receive meal plan recommendations as part of structured programs. Sirka aims to empower Indonesians to lead healthier lives by improving weight management and enhancing control over chronic conditions.

the first high-tech company in China to focus on the treatment of cerebrovascular disease, it has more than four years of product research and development, leading China's cerebrovascular disease intelligence in an all-around way. vertical field of diagnosis and treatment. It has become a well-known brain stroke intelligence diagnosis and treatment platform in China.

Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency

Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects to continuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization. It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.

NeuroXess is a high-tech life science company focusing on flexible electrode BCI (Brain-computer interface) technologies to protect and explore the brain.

Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases.

Vico Medical is a medical device firm providing R&D and production of medical devices for cardiovascular and cerebrovascular diseases.

Dangsheng New Material is a high-performance fiber material developer and a high-tech enterprise dedicated to the development, production and sales of high-performance fiber materials. It has realized the production of China's only high-performance anti-virus and biochemical barrier protective clothing made of a single material. . Dangsheng New Materials provides a series of medical disposable protective products, including protective clothing, isolation clothing, protective shoe covers and other supplies.

ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, established in 2016. The company specializes in offering a range of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and tools for western blotting. Additionally, ABclonal provides peptide, antibody, and protein services. The company distributes its products through a network that spans Europe, Asia, North America, and Oceania. With a team of scientists from leading universities, ABclonal is committed to enhancing the quality of life science research through its high-quality offerings.

Pristyn Care is a Health Care Startup that is disrupting Day Care Procedures. It is founded by Ex Consultant Surgeons from Medanta, Max, Birla and ex UrbanClap, Mobikwik Strategy & Business Head. Pristyn Care's team is young and passionate, and we see massive opportunity in the healthcare industry. By leveraging technology, and a set of simple yet powerful processes and operations, we wish to build an ecosystem which can organize the world of day care procedures. We are leveraging some of the most advanced tech developments in the field of healthcare for this goal.

SyMap Medical focuses on developing and manufacturing a proprietary catheter-based system for renal mapping and ablation, specifically aimed at treating hypertension and various other serious conditions, including heart failure, arrhythmia, and renal failure. The company's core technology platform is based on radiofrequency (RF) ablation, which is integral to its approach in renal nerve mapping and selective ablation. This innovative medical device is designed to enhance treatment options for patients suffering from these significant health issues.

Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts and process development experience. It is committed to the development and production of serum-free media for new animal cells, while providing formula production and technical support for the biopharmaceutical industry. With ancillary services, the products include basic media such as S1, S2, S3, S3-CD and S4, as well as 2×103 feeds and other feed media based on 2×103 feeds; and customized services.

Mosaic Wellness is a digital health platform that operates a collection of health clinics focused on enhancing well-being for specific demographics in India. The company aims to empower individuals through personalized solutions that address particular health needs. It offers services such as medical consultations, wellness assessments, and hygiene products, all accessible via its digital platform. Each clinic, including those targeting men and women, strives to provide essential resources that support a fulfilling and healthy lifestyle. Mosaic Wellness is dedicated to helping individuals navigate their health journeys with a focus on purpose and wellness.

Suzhou Xinqing Medical Technology Co., Ltd., founded in 2017 by Dr. Xu Bozhen, focuses on the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular illnesses. The company specializes in creating short-term to medium-term ventricular assist devices that leverage advanced fluid mechanics and magnetic suspension technology. These innovations allow the devices to be compatible with various blood types, thereby reducing the risk of incompatibility for patients. With a team of leading experts in artificial heart engineering, the company has successfully developed an artificial heart that holds independent intellectual property rights, positioning itself as a key player in the medical technology sector.

OriGynMED provides deep professional resources for the invested companies through its global ecosystem to help the business development of the companies. It is a technology-based medical company.

Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer and stem cell therapies for degenerative diseases, particularly in Greater China. The company utilizes proprietary cell-based technologies to create treatments, including various forms of CAR-T therapies targeting different cancer types, such as CD20 for anti-tumor activities, CD22 for B cell malignancies, and therapies aimed at refractory multiple myeloma. Additionally, the company develops NKG2D CAR therapies and treatments for hepatocellular carcinoma, alongside knee osteoarthritis therapies currently undergoing clinical trials. Beyond its therapeutic development, Cellular Biomedicine Group is involved in biopharmaceutical activities encompassing research and development, technical support, and the manufacturing of pharmaceutical products and medical devices. It also operates under a collaboration agreement with Novartis Pharma AG to manufacture and supply the CAR-T cell therapy Kymriah in China. Established in 2001, the company integrates over thirty years of research and clinical experience in cellular medicine, drawing on expertise from collaborations among scientists and medical professionals across the United States, England, and China.

Yuanxin Huibao is a health insurance technology service provider that specializes in medical insurance, particularly for major and chronic diseases. The company offers a comprehensive suite of services that includes special drug services, video consultations, welfare drugs, and claims investigations. By integrating these features, Yuanxin Huibao aims to deliver reliable medical services and improve insurance coverage for its users. Additionally, the company provides insurance firms with a one-stop solution for risk control and actuarial pricing, enhancing the overall efficiency and effectiveness of the health insurance process.

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

Westlake Therapeutics is a biopharmaceutical company based in Hangzhou, China, founded in 2019. The company specializes in cell therapy, focusing on developing innovative treatments for rare diseases, cancer, and various immunological and metabolic disorders. Central to its approach is the REDx platform, which utilizes engineered red blood cell technology. This platform enables the genetic engineering of hematopoietic stem and progenitor cells sourced from peripheral blood, bone marrow, or cord blood. By leveraging this technology, Westlake Therapeutics aims to create personalized therapies that enhance treatment options for patients facing a wide range of health challenges.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

Biosysen is a synthetic biology company specializing in software-based species design and biomanufacturing. The company utilizes software engineering principles to enhance the self-replication and scalability of biological systems, aiming to unlock the full productivity potential of the biological industry. Biosysen's primary offerings include a library of artificial species and related industrial pipelines tailored for specific applications. These products cater to various sectors, including food production, medical testing, daily chemicals, and protein drug development, thereby supporting innovation and efficiency in these industries.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

XISOFT is a professional manufacturer specializing in informatization and data services within health economic management. The company develops an enterprise resource planning (ERP) platform tailored for hospitals, providing comprehensive management and monitoring capabilities across various functions, including finance, supply chain, human resources, and diagnosis-related groups. By leveraging technology, XISOFT aims to support medical institutions in streamlining operations and enhancing efficiency. Its platform enables effective business integration and refined management, addressing key areas such as intelligent finance, material assets, internal control, and event management. Through its innovative solutions, XISOFT assists healthcare providers in realizing their strategic objectives and improving overall operational effectiveness.

Analytical Biosciences is a single-cell genome developer that aims to create and apply accurate maps of human diseases. In collaboration with medical research institutions, hospitals, and pharmaceutical companies, we are committed to exploiting the application of single-cell genomics and bioinformatics in the diagnosis and treatment of human diseases. Through large-scale systematic disease single-cell mapping, big data intelligence mining is carried out to help a wide range of partners discover new therapeutic targets and develop new treatment strategies.

Phanes Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2016. The company specializes in drug discovery and early development, primarily in the fields of immuno-oncology and eye diseases. Phanes Therapeutics is developing a range of therapeutic molecules, including a monoclonal antibody aimed at treating solid tumors, as well as therapies for age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, the company is working on bispecific antibodies targeting small cell lung cancer. Through its extensive scientific expertise and innovative approaches, Phanes Therapeutics aims to create effective treatment options that enhance patient care and improve outcomes for those suffering from various conditions.

Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.

VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

Pristyn Care is a Health Care Startup that is disrupting Day Care Procedures. It is founded by Ex Consultant Surgeons from Medanta, Max, Birla and ex UrbanClap, Mobikwik Strategy & Business Head. Pristyn Care's team is young and passionate, and we see massive opportunity in the healthcare industry. By leveraging technology, and a set of simple yet powerful processes and operations, we wish to build an ecosystem which can organize the world of day care procedures. We are leveraging some of the most advanced tech developments in the field of healthcare for this goal.

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancer patients around the world. It is founded by Bing Yuan, Eric Slosberg, and Andy Fu.

Vibrant Gastro is a company focused on developing and producing a chemical-free vibrating capsule designed to treat constipation. The innovative capsule aims to address the fundamental physiological aspects of constipation, promoting natural bowel activity without relying on chemical supplements or disrupting the body’s internal balance. Leveraging extensive knowledge in gastrointestinal health and motility, Vibrant Gastro offers a novel solution for individuals seeking effective relief from constipation while maintaining a commitment to chemical-free treatment options.

ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, established in 2016. The company specializes in offering a range of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and tools for western blotting. Additionally, ABclonal provides peptide, antibody, and protein services. The company distributes its products through a network that spans Europe, Asia, North America, and Oceania. With a team of scientists from leading universities, ABclonal is committed to enhancing the quality of life science research through its high-quality offerings.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

D3 Bio is a biotechnology company dedicated to the discovery, development, and registration of innovative medicines in oncology and immunology. The company aims to address existing gaps in conventional treatments by utilizing clinical and market data to identify areas for improvement. D3 Bio employs unique drug development methodologies that target new diseases and delivery methods, ultimately providing patients with alternative therapeutic options in these critical areas of healthcare.

Pristyn Care is a Health Care Startup that is disrupting Day Care Procedures. It is founded by Ex Consultant Surgeons from Medanta, Max, Birla and ex UrbanClap, Mobikwik Strategy & Business Head. Pristyn Care's team is young and passionate, and we see massive opportunity in the healthcare industry. By leveraging technology, and a set of simple yet powerful processes and operations, we wish to build an ecosystem which can organize the world of day care procedures. We are leveraging some of the most advanced tech developments in the field of healthcare for this goal.

Dizal Pharmaceutical is a research-focused biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines. The company is involved in all stages of drug development, from research and development to production and sales, aiming to create first-in-class and best-in-class therapeutic solutions. Based in Jiangsu, China, Dizal Pharmaceutical is committed to advancing healthcare through its innovative drug portfolio.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer. The company uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simcha’s lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020. It was founded in 2018 and is headquartered in New Haven, Connecticut, USA.

Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, that specializes in developing, manufacturing, and promoting cell-based immunotherapies aimed at treating cancer. The company leverages advanced technologies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, to enhance the body's immune response against cancer. JW Therapeutics focuses on addressing both hematological cancers and solid tumors, with its leading product candidate being relmacabtagene autoleucel, designed as a potential superior anti-CD19 CAR-T therapy. The company's mission is to improve patient outcomes and quality of life for those battling cancer through innovative treatment solutions.

SiBionics is a medtech company based in Shenzhen, China, focused on the research and development of active implantable medical devices and medical artificial intelligence. The company specializes in creating innovative solutions for various health conditions, including retinitis pigmentosa, diabetes, cardiovascular diseases, and gastrointestinal tumors. SiBionics develops artificial intelligence technologies for medical imaging and implantable devices, including retinal electrical stimulators and continuous glucose monitors. Their work also encompasses health management, disease screening, and diagnostics, using approaches such as visual coding, medical imaging AI, and big data analytics to enhance patient care and address chronic diseases. Through these advancements, SiBionics aims to provide cost-effective products that improve long-term monitoring and treatment options in the medical field.

CERo Therapeutics, Inc. is a new cellular immunotherapy company. We have created a hybrid platform that integrates innate and adaptive programs to eliminate disease.

Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. The company's innovative technologies focus on the analysis and manipulation of individual immune cells, enabling advancements in immune and cell therapy. By precisely monitoring and modulating the immune system, RootPath aims to enhance the diagnosis and treatment of cancer, contributing to significant improvements in patient outcomes.

BGI is a biotechnology company specializing in genomics, providing genome sequencing and genetic testing services to research institutions and healthcare professionals. Operating through its subsidiary, Shenzhen Huada Gene Technology Co. Ltd., BGI offers a wide range of services including bioinformatics testing, agricultural genomics research, and proteomics research. The company collaborates with various organizations to enhance research efforts in the pharmaceutical and healthcare sectors. BGI also supplies products such as DNA extraction kits and other related tools, positioning itself as a key player in advancing genetic and genomic research.

Pristyn Care is a Health Care Startup that is disrupting Day Care Procedures. It is founded by Ex Consultant Surgeons from Medanta, Max, Birla and ex UrbanClap, Mobikwik Strategy & Business Head. Pristyn Care's team is young and passionate, and we see massive opportunity in the healthcare industry. By leveraging technology, and a set of simple yet powerful processes and operations, we wish to build an ecosystem which can organize the world of day care procedures. We are leveraging some of the most advanced tech developments in the field of healthcare for this goal.

ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.

Mosaic Wellness is a digital health platform that operates a collection of health clinics focused on enhancing well-being for specific demographics in India. The company aims to empower individuals through personalized solutions that address particular health needs. It offers services such as medical consultations, wellness assessments, and hygiene products, all accessible via its digital platform. Each clinic, including those targeting men and women, strives to provide essential resources that support a fulfilling and healthy lifestyle. Mosaic Wellness is dedicated to helping individuals navigate their health journeys with a focus on purpose and wellness.

Vim, Inc. is a healthcare technology company founded in 2015 and based in San Francisco, California. The company develops a platform that enhances the connection between patients and healthcare providers by offering online services for finding, scheduling, and receiving care. Its solutions include online booking and referral coordination, facilitating seamless communication and data sharing among health plans, patients, and a wide range of medical providers, from independent practitioners to large healthcare systems. Vim's platform integrates with electronic health records, enabling real-time access to patient data and insights at the point of care. By improving connectivity within clinical operations, Vim aims to support the delivery of affordable, high-quality healthcare.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Pristyn Care is a Health Care Startup that is disrupting Day Care Procedures. It is founded by Ex Consultant Surgeons from Medanta, Max, Birla and ex UrbanClap, Mobikwik Strategy & Business Head. Pristyn Care's team is young and passionate, and we see massive opportunity in the healthcare industry. By leveraging technology, and a set of simple yet powerful processes and operations, we wish to build an ecosystem which can organize the world of day care procedures. We are leveraging some of the most advanced tech developments in the field of healthcare for this goal.

Yuanxin Huibao is a health insurance technology service provider that specializes in medical insurance, particularly for major and chronic diseases. The company offers a comprehensive suite of services that includes special drug services, video consultations, welfare drugs, and claims investigations. By integrating these features, Yuanxin Huibao aims to deliver reliable medical services and improve insurance coverage for its users. Additionally, the company provides insurance firms with a one-stop solution for risk control and actuarial pricing, enhancing the overall efficiency and effectiveness of the health insurance process.

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in developing first-in-class new chemical entities (NCEs) aimed at treating diseases that currently lack effective therapeutic options. Utilizing its proprietary uSMITE™ platform, Cullgen focuses on small molecule therapeutics that employ targeted protein degradation technology. This innovative approach selectively degrades disease-causing proteins, offering potential treatments for cancer, inflammatory, and autoimmune diseases, including targets that have been previously deemed undruggable. By advancing drug discovery in these challenging areas, Cullgen aims to provide novel therapeutic approaches to improve patient outcomes.

Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

VoxelCloud Inc. is a company specializing in cloud computing and artificial intelligence solutions aimed at enhancing the interpretation of medical images and clinical data for healthcare professionals. Founded in 2015 and headquartered in Los Angeles, California, VoxelCloud provides automated medical image analysis and diagnostics services utilizing proprietary algorithms and deep learning techniques. The company focuses on critical clinical areas, including lung cancer, diabetic retinopathy, coronary heart disease, and liver disease, ensuring that medical practitioners receive accurate and timely insights. In addition to its Los Angeles base, VoxelCloud has offices in Shanghai and Suzhou, China, and maintains a research and development team in Phoenix, further expanding its capabilities in the healthcare sector.

RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. The company's innovative technologies focus on the analysis and manipulation of individual immune cells, enabling advancements in immune and cell therapy. By precisely monitoring and modulating the immune system, RootPath aims to enhance the diagnosis and treatment of cancer, contributing to significant improvements in patient outcomes.

Medical Alliance is a post of physician social service platform. Users are certified doctors working in the Medical Alliance, they can share knowledge, experience and insights with the other industry elite, to continue to provide high quality content for each other. Application provides a medical quiz, map that case, the anonymous social circles and doctors and other functions, is committed to helping physicians groups, more convenient access to high-quality information from the industry

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of medicines for chronic illnesses, particularly infectious diseases, liver, and lung conditions. Founded in 2018, the company operates from Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to provide innovative biopharmaceutical solutions tailored to the needs of Chinese patients, addressing public health challenges such as hepatitis B, HIV, and multidrug-resistant infections. The company leverages technology and data to enhance the Chinese healthcare system, ensuring better access to effective treatments. With a diverse pipeline of over ten product candidates, Brii Biosciences is committed to improving health outcomes for patients suffering from both infectious and central nervous system diseases.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

CStone Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing innovative immuno-oncology and molecularly targeted drugs aimed at addressing significant unmet medical needs in cancer treatment. Founded in 2015 and headquartered in Shanghai, China, the company has established a robust product pipeline that includes several late-stage clinical candidates, such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, which targets programmed death receptor. Other notable products include ivosidenib, avapritinib, and pralsetinib, along with a variety of additional investigational drugs for solid tumors and other cancer indications. CStone engages in strategic collaborations, including a licensing agreement with Numab Therapeutics for a tri-specific antibody and a clinical partnership with Bayer HealthCare to assess the efficacy of CS1001 in combination therapies. The company aims to enhance treatment options for cancer patients both in China and globally through its dedicated research and development efforts.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.

Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, that specializes in developing, manufacturing, and promoting cell-based immunotherapies aimed at treating cancer. The company leverages advanced technologies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, to enhance the body's immune response against cancer. JW Therapeutics focuses on addressing both hematological cancers and solid tumors, with its leading product candidate being relmacabtagene autoleucel, designed as a potential superior anti-CD19 CAR-T therapy. The company's mission is to improve patient outcomes and quality of life for those battling cancer through innovative treatment solutions.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.